ALS was given the remit of managing the fund and making Wales an attractive destination for UK and international companies operating in the sector.
Since its inception, the WLSIF has:
Created a portfolio of 10 investments.
Delivered an internal rate of return (IRR) of 26% (3-year IRR at 31 March 2016)
Attracted £380m UK and international co-investment
Created 150 high-tech and highly skilled jobs and aims to create a further 200
Established a portfolio of 23 highly valuable therapeutic products and medical devices currently under development for stroke, cancer, blindness, respiratory disease, vascular disease, cystic fibrosis and diabetes
Built this success on an initial investment of £45m